Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients
The high reliability of our signature to predict response and PFS after ICI treatment was demonstrated using experimental and 3 independent datasets. Additionally, annotated molecular profiles obtained in this study were made publicly accessible.
Authors
- Alexander Simonov (ORCID: https://orcid.org/0000-0003-1445-3177)
- Anna Semenova (ORCID: https://orcid.org/0000-0003-4951-3053)
- Marina A. Lyadova (ORCID: https://orcid.org/0000-0002-9558-5579)
- Aleksey Moisseev
- Elena Poddubskaya (ORCID: https://orcid.org/0000-0001-6476-6337)
- Maxim Sorokin (ORCID: https://orcid.org/0000-0001-7685-3446)
- Andrew Garazha (ORCID: https://orcid.org/0000-0001-9679-149X)
- Anastasia Guryanova (ORCID: https://orcid.org/0000-0002-6589-2164)
- Vladimir Lyadov (ORCID: https://orcid.org/0000-0002-7281-3591)
- Maria Suntsova
- M. Biakhova
- Anton Buzdin
- V.G. Shatalov
- Daniil Luppov
Institutions
- Moscow Institute of Physics and Technology (RU)
- Sechenov University (RU)
- Endocrinology Research Center (RU)
- Institute of Bioorganic Chemistry (RU)
- Russian Medical Academy of Continuous Professional Education (RU)
- European Organisation for Research and Treatment of Cancer (BE)
- Moscow City Oncology Hospital №62 (RU)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.3389/fimmu.2024.1493877
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.13